The big debate: Where to spend scarce resources
The big debate: Where to spend scarce resources
Cooperating towards control plans in Myanmar
PD-1 therapy with eribulin for triple negative MBC
Women experiencing menopause symptoms less likely to adhere to medication
Breast cancer mortality declining globally
Everolimus extends PFS for HR positive, HER2 negative breast cancer
TEAM IIb trial results: Adjuvant ibandronate in early breast cancer
Neoadjuvant abemaciclib for HR positive, HER negative breast cancer
TCHP with/out oestrogen for HR/HER positive breast cancer
Efficacy of veliparib with carboplatin and paclitaxel for BRCA1/2 mutations in metastatic breast cancer
Whole exome and transcriptome sequencing of resistant ER positive metastatic breast cancer
ASH 2016: Multiple myeloma highlights